CA3128940C - Compositions pharmaceutiques comprenant du meloxicam - Google Patents

Compositions pharmaceutiques comprenant du meloxicam Download PDF

Info

Publication number
CA3128940C
CA3128940C CA3128940A CA3128940A CA3128940C CA 3128940 C CA3128940 C CA 3128940C CA 3128940 A CA3128940 A CA 3128940A CA 3128940 A CA3128940 A CA 3128940A CA 3128940 C CA3128940 C CA 3128940C
Authority
CA
Canada
Prior art keywords
dosage form
meloxicam
rizatriptan
migraine
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3128940A
Other languages
English (en)
Other versions
CA3128940A1 (fr
Inventor
Herriot TABUTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axsome Therapeutics Inc
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71947112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3128940(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Priority to CA3213549A priority Critical patent/CA3213549A1/fr
Publication of CA3128940A1 publication Critical patent/CA3128940A1/fr
Application granted granted Critical
Publication of CA3128940C publication Critical patent/CA3128940C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne des compositions comprenant un anti-inflammatoire non stéroïdien (AINS), tel que le méloxicam et/ou le rizatriptan, en association avec une cyclodextrine et/ou un carbonate ou un bicarbonate. Ces compositions peuvent être administrées par voie orale, par exemple, pour améliorer la biodisponibilité ou la pharmacocinétique de l'AINS dans le traitement de la douleur, par exemple la migraine, l'arthrite, et d'autres états pathologiques. L'invention concerne également des procédés de traitement de la douleur, tels que la migraine, comprenant l'administration de méloxicam et de rizatriptan à un être humain souffrant de douleur, par exemple de migraine. Pour la migraine, ces procédés peuvent être particulièrement utiles lorsque le méloxicam et le rizatriptan sont administrés pendant que l'être humain souffre d'une attaque aiguë de douleur migraineuse ou de migraine avec aura. Selon certains modes de réalisation, la combinaison de méloxicam et de rizatriptan peut être administrée de manière à obtenir un Tmax de méloxicam de 3 heures ou moins.
CA3128940A 2019-02-06 2020-02-06 Compositions pharmaceutiques comprenant du meloxicam Active CA3128940C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3213549A CA3213549A1 (fr) 2019-02-06 2020-02-06 Compositions pharmaceutiques comprenant du meloxicam

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201962802198P 2019-02-06 2019-02-06
US62/802,198 2019-02-06
US201962803756P 2019-02-11 2019-02-11
US62/803,756 2019-02-11
US201962835613P 2019-04-18 2019-04-18
US62/835,613 2019-04-18
US201962846311P 2019-05-10 2019-05-10
US62/846,311 2019-05-10
US201962860705P 2019-06-12 2019-06-12
US62/860,705 2019-06-12
US201962895933P 2019-09-04 2019-09-04
US201962895956P 2019-09-04 2019-09-04
US62/895,933 2019-09-04
US62/895,956 2019-09-04
US201962955905P 2019-12-31 2019-12-31
US62/955,905 2019-12-31
PCT/US2020/017046 WO2020163620A1 (fr) 2019-02-06 2020-02-06 Compositions pharmaceutiques comprenant du méloxicam

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3213549A Division CA3213549A1 (fr) 2019-02-06 2020-02-06 Compositions pharmaceutiques comprenant du meloxicam

Publications (2)

Publication Number Publication Date
CA3128940A1 CA3128940A1 (fr) 2020-08-13
CA3128940C true CA3128940C (fr) 2023-11-07

Family

ID=71947112

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3213549A Pending CA3213549A1 (fr) 2019-02-06 2020-02-06 Compositions pharmaceutiques comprenant du meloxicam
CA3128940A Active CA3128940C (fr) 2019-02-06 2020-02-06 Compositions pharmaceutiques comprenant du meloxicam

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3213549A Pending CA3213549A1 (fr) 2019-02-06 2020-02-06 Compositions pharmaceutiques comprenant du meloxicam

Country Status (19)

Country Link
EP (1) EP3920909A4 (fr)
JP (5) JP7237386B2 (fr)
KR (2) KR20210118880A (fr)
CN (1) CN113423397A (fr)
AU (3) AU2020218253B2 (fr)
BR (1) BR112021015467A2 (fr)
CA (2) CA3213549A1 (fr)
CL (1) CL2021002070A1 (fr)
CO (1) CO2021010380A2 (fr)
CR (1) CR20210420A (fr)
EC (1) ECSP21060962A (fr)
IL (1) IL285389A (fr)
MA (1) MA54904A (fr)
MX (2) MX2021009435A (fr)
MY (1) MY198967A (fr)
NZ (1) NZ778435A (fr)
PE (1) PE20212157A1 (fr)
SG (1) SG11202107926XA (fr)
WO (1) WO2020163620A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230125826A (ko) * 2020-12-31 2023-08-29 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물
KR20260074736A (ko) * 2023-09-18 2026-05-26 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234324T3 (es) * 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
WO2004089365A1 (fr) 2003-04-11 2004-10-21 Pfizer Limited Combinaison pharmaceutique a base d'eletriptan et de bicarbonate de sodium
BRPI0410807A (pt) 2003-06-06 2006-06-27 Glaxo Group Ltd composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica
EP3216445A1 (fr) 2004-05-28 2017-09-13 Imaginot Pty Ltd. Système d'administration d'un composé thérapeutique oral
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
PL3100728T3 (pl) * 2009-05-13 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
SG10202010157VA (en) * 2015-02-10 2020-11-27 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
SMT202600087T1 (it) * 2016-09-23 2026-03-09 Teva Pharmaceuticals Int Gmbh Trattamento dell’emicrania refrattaria
US10471014B2 (en) * 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
DK3565550T3 (da) * 2017-01-04 2021-01-18 Axsome Therapeutics Inc Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
KR102583443B1 (ko) * 2017-05-10 2023-09-26 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학적 조성물

Also Published As

Publication number Publication date
JP2022519670A (ja) 2022-03-24
JP2023062144A (ja) 2023-05-02
MA54904A (fr) 2021-12-15
BR112021015467A2 (pt) 2021-10-05
JP7420990B2 (ja) 2024-01-23
JP7237386B2 (ja) 2023-03-13
EP3920909A1 (fr) 2021-12-15
CR20210420A (es) 2021-12-22
MX2021009435A (es) 2021-09-10
AU2020218253A1 (en) 2021-08-12
JP7862619B2 (ja) 2026-05-19
JP2026116506A (ja) 2026-07-09
JP2024026732A (ja) 2024-02-28
CN113423397A (zh) 2021-09-21
PE20212157A1 (es) 2021-11-09
NZ778435A (en) 2024-12-20
CA3213549A1 (fr) 2020-08-13
SG11202107926XA (en) 2021-08-30
KR20210118880A (ko) 2021-10-01
IL285389A (en) 2021-09-30
AU2023202545A1 (en) 2023-05-18
MY198967A (en) 2023-10-05
MX2026005800A (es) 2026-06-01
KR20260066814A (ko) 2026-05-12
WO2020163620A1 (fr) 2020-08-13
CA3128940A1 (fr) 2020-08-13
AU2020218253B2 (en) 2023-02-23
AU2025230695A1 (en) 2025-10-02
CO2021010380A2 (es) 2021-09-30
JP7620125B2 (ja) 2025-01-22
ECSP21060962A (es) 2021-11-30
EP3920909A4 (fr) 2022-11-30
CL2021002070A1 (es) 2022-04-01
JP2025061137A (ja) 2025-04-10
AU2023202545B2 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
US10780166B2 (en) Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) Pharmaceutical compositions comprising meloxicam
US11426414B2 (en) Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) Pharmaceutical compositions comprising meloxicam
US11369684B2 (en) Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) Pharmaceutical compositions comprising meloxicam
US11207328B2 (en) Pharmaceutical compositions comprising meloxicam
US11357854B2 (en) Pharmaceutical compositions comprising meloxicam
US11123431B2 (en) Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) Pharmaceutical compositions comprising meloxicam
US11285214B2 (en) Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) Pharmaceutical compositions comprising meloxicam
US20210275670A1 (en) Pharmaceutical compositions comprising meloxicam
AU2021414212A9 (en) Pharmaceutical compositions comprising meloxicam
CA3179681A1 (fr) Compositions pharmaceutiques comprenant du meloxicam
AU2025230695A1 (en) Pharmaceutical compositions comprising meloxicam
WO2025221509A1 (fr) Compositions pharmaceutiques contenant du méloxicam

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210803

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 4TH ANNIV.) - SMALL

Year of fee payment: 4

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-T10-T11-T103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME TO TOP-UP SMALL ENTITY FEES REQUEST RECEIVED

Effective date: 20240822

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240822

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20240822

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - SMALL

Year of fee payment: 5

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250127

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250127

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250127

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250411

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 2ND ANNIV.) - SMALL

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251216

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260105

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260109

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: A-4-4-T10-T13-T104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME TO TOP-UP SMALL ENTITY FEES REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260512

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260512